The Addition of Cixutumumab or Temozolomide to Intensive Multiagent Chemotherapy Is Feasible but Does Not Improve Outcome for Patients with Metastatic Rhabdomyosarcoma: A Report from the Children’s Oncology Group

PURPOSE: Outcome for patients with metastatic rhabdomyosarcoma (RMS) remains poor. A previous COG study (ARST0431) for patients with metastatic RMS showed no improvement in outcome using multiple cytotoxic agents in a dose intensive manner. We report the results of the subsequent COG study (ARST08P1...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Malempati, Suman, Weigel, Brenda J., Chi, Yueh-Yun, Tian, Jing, Anderson, James R., Parham, David M., Teot, Lisa A., Rodeberg, David A., Yock, Torunn I., Shulkin, Barry L., Spunt, Sheri L., Meyer, William H., Hawkins, Douglas S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6329653/
https://ncbi.nlm.nih.gov/pubmed/30351457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31770
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares